StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)

Close on Nov 18, 2026Market cap $113.58MP/E –Yield –

Atrium Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$6.63M–
Q2 FY2026Jun 30, 2026-$22.62M–
Q1 FY2026Mar 31, 2026-$17.28M–
Q3 FY2025Sep 30, 2025-$213.00K–
Q2 FY2025Jun 30, 2025-$12.86M–
Q1 FY2025Mar 31, 2025-$7.45M–

More Atrium Therapeutics figures

See a number that looks wrong?